Skip Ribbon Commands
Skip to main content

Terumo Appoints EU based Subsidiary's Associate as the Newest Terumo Fellow

5/22/2019 - Tokyo, Japan

Terumo Corporation (TSE: 4543) today announced that it has appointed an associate of Terumo Europe NV as the newest "Terumo Fellow". Terumo instituted the Terumo Fellow program to recognize associates who have made outstanding contributions leading to innovation in healthcare, and in the technology, research, clinical, and regulatory affairs, of Terumo Group. Terumo created the program in 2016 and this is the sixth individual appointed.
Terumo will recognize Fien Aerts, Vice President Regulatory, Complaint and Vigilance of Terumo EMEA as the newest Terumo Fellow. She joined Terumo in 1983, and is well acknowledged for establishing the foundation of Terumo's quality management system and regulatory affairs. Ms. Aerts has been the leading figure for Terumo's first drug-eluting stent to acquire a CE mark, and her great leadership continues to take impact globally. Her unchanging pursuit for top quality, and her expertise in healthcare regulation has contributed to the registration of numerous products Terumo provides today.

Terumo holds "Quality - committed to excellence" as one of the Core Values, which are shared by and connect Terumo associates worldwide. To ensure safety and reliability, we will continue to contribute to healthcare, by encouraging technology, research, clinical and regulatory affairs advancement.


About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.


(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.